#USA #Fremont #Alamar Biosciences #Precision Proteomics #Stephen Williams

Alamar Biosciences Secures Over $50 Million Funding and Strengthens Leadership Team

FREMONT, California, January 12, 2026/PRNewswire/ – Alamar Biosciences, Inc. has successfully closed an oversubscribed financing round via convertible bonds, bringing in over $50 million in new capital. The round saw participation from existing investors like Illumina Ventures and Sands Capital, as well as new participants such as T. Rowe Price Investment Management, Inc. and Braidwell LP. The funds raised in this financing will significantly expedite the commercial development of Alamar's precision proteomics platform, which focuses on advancing the early detection of diseases.

In a statement, Dr. Yuling Luo, founder, chairman, and CEO of Alamar, expressed gratitude for the unwavering support from existing investors and welcomed new partners to the fold. He emphasized that their confidence in the company's vision and strategy highlights the transformative potential of Alamar’s work. This investment will bolster innovation efforts and continue expanding the reach of their platform to unlock the full value of precision medicine and early disease detection.

Expansion of Leadership Team

Along with this funding announcement, Alamar also revealed key expansions in their executive leadership and board of directors to support the company’s growth and emphasis on operational excellence.

Stephen Williams, M.D., Ph.D., joins Alamar as the Chief Scientific Officer. With over three decades of experience in precision medicine and biomarker innovations, Steve was most recently the Medical Director at Standard BioTools and previously held leadership roles at Pfizer for 18 years. A recognized figure within the scientific community, he has served on the National Advisory Council for Biomedical Imaging and Bioengineering at the NIH, contributed to the launch of the Alzheimer’s Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.

In addition, Alamar has appointed Rebecca Chambers and Frank Witney, Ph.D., as members of the board. Rebecca, the current CFO of Veracyte, brings extensive finance and healthcare management experience from her previous roles at Outset Medical, Illumina, Myriad Genetics, and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, has over three decades of management experience in the life sciences sector and has previously served as CEO and president at Affymetrix and Dionex Corporation. He currently holds board positions at Revvity, Cerus Corporation, Standard BioTools, and various private companies.

Dr. Luo expressed excitement about Stephen joining the team and welcoming Rebecca and Frank to the board. “Their expertise and diverse perspectives will be invaluable in accelerating our mission to harness the potential of our Precision Proteomics platform to make a significant impact on health and disease,” he stated. This is indeed a thrilling time for Alamar, and we look forward to the contributions their leadership will bring to innovation and growth.

About Alamar Biosciences, Inc.

Alamar Biosciences is a private life sciences company dedicated to advancing precision proteomics to facilitate early disease detection. The company utilizes its proprietary NULISA™ technology alongside the ARGO™ HT System, designed to deliver exceptional sensitivity and address key limitations of existing technologies in the field of precision proteomics. For more information, visit alamarbio.com.